Navigation Links
Vanda Presents Phase III Iloperidone Efficacy Data
Date:12/12/2007

Findings also demonstrate favorable safety and tolerability profile

ROCKVILLE, Md., Dec. 12 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that data from four Phase III efficacy and safety trials demonstrate that iloperidone, an investigational atypical antipsychotic, is associated with significantly greater improvements in the symptoms of schizophrenia versus placebo and has a favorable safety and tolerability profile. These results were included as part of the recently filed New Drug Application (NDA) for iloperidone and were presented for the first time this week at a major psychiatric congress. Posters containing the data presented will be posted on Vanda's Web site, http://www.vandapharma.com, on Thursday, December 13, 2007. The U.S. Food and Drug Administration (FDA) accepted the NDA submitted by Vanda for marketing approval on November 26, 2007.

The Phase III study conducted by Vanda evaluated the efficacy of iloperidone versus placebo in patients with schizophrenia. The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24 mg/day, ziprasidone at 160 mg/day, or placebo. Patients treated with iloperidone had significantly greater improvements in Positive and Negative Syndrome Scale-Total (PANSS-T) scores than those on placebo and had PANSS-T improvement comparable to ziprasidone.

"There is a great need for new treatment options for schizophrenia, particularly as patients often discontinue treatment due to efficacy and tolerability issues, as seen in the NIMH-funded
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... de noviembre de 2014  BioClinica®, Inc., un ... y tecnologías eClinical, ha indicado un aumento de ... para el seguimiento basado en el riesgo en ... concepto del seguimiento basado en el riesgo más ... de seguimiento o cambio de los métodos de ...
(Date:11/22/2014)... 21, 2014 Research and Markets  has announced ... Industry Report, 2014-2017" report to their offering. ... Chinese recombinant protein drug market has been expanding rapidly ... and the like. During 2005-2013, sales of recombinant protein ... CAGR of 19.1%, and it is projected that ...
(Date:11/21/2014)... SAN DIEGO , Nov. 21, 2014 /PRNewswire/ ... TNDM ), a medical device company and ... today announced a partnership with Tidepool, a non-profit ... an open source software platform that increases diabetes ... the Tidepool Platform, which is currently under development, ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
... Codexis, Inc. (Nasdaq: CDXS ) today announced the ... to be held in New York, NY on May 18-19, ... will appear on a panel titled "Biofuels" scheduled for May ... not been provided by the conference organizers. Further information will ...
... Pa., May 4, 2011 Auxilium Pharmaceuticals, Inc. (Nasdaq: ... will participate in the Bank of America Merrill Lynch ... the Encore at Wynn Las Vegas.  Mr. Armando Anido, ... an overview of the Company and its product pipeline ...
Cached Medicine Technology:Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 2Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference 3
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier ... collection of 2014 Evening Dresses. All these fresh items ... company’s marketing manager, the special offer is valid until ... , Sweetdressy.com has been working well in the fashion ... latest designs. Their new dresses may be the best ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... BC (PRWEB) November 23, 2014 Pro Ace ... announced that it will now be providing an 8 year ... of hot water tank installations went up due to the ... to assure its customers of the premium service that the ... offering 8 year warranty on John Wood and Bradford hot ...
(Date:11/23/2014)... This evaluation provides a basic conclusion ... and manufacturing technological innovation. Then, the evaluation investigates ... in information. In this part, the evaluation provides ... and 2009-2014 market shares for each company. Through ... and Chinese suppliers finish market of Femoral Occurs ...
Breaking Medicine News(10 mins):Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 2Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 3Health News:Femoral Stems Industry 2014 Analysis & 2019 Forecasts for Global and Chinese Region in New Research Report at ReportsnReports.com 4
... transplantation of stem cells from a healthy donor (allogeneic) ... aggressive form of chronic lymphocytic leukemia (CLL), irrespective of ... disease. The German CLL Study Group proved this in ... Dr. Peter Dreger, senior consultant and head of the ...
... evaluating the effectiveness of a broad selection of popular ... has found no evidence that any of them facilitate ... presented today (Monday) at the International Congress on Obesity ... effective than the fake supplements they were compared with. ...
... cancer patients who reported poor sleep quality one year after ... dry mouth related to radiation treatments, according to a recent ... Because these side effects can be controlled or modified, the ... cancer patients may be warranted to improve sleep hygiene and ...
... immediate antiretroviral treatment (ART) for infected individuals could have a ... a new study finds that it would not halt the ... a paper that will appear in the August 15 issue ... online, researchers find that the so-called "test-and-treat" strategy could reduce ...
... ... company (Pink Sheets: GDAR), has terminated it,s previously announced strategic alliance with JK Development ... ... Inc., a publicly traded company (Pink Sheets: GDAR), has terminated it,s previously announced strategic ...
... The Kristen Renee ... local campaign set out to fight for the city residents continues to fight for answers ... and BBQ., , ... 9, 2010 -- The Kristen Renee Foundation has launched a campaign to research and investigate ...
Cached Medicine News:Health News:Stem cell transplantation of therapy-resistant chronic leukemia successful 2Health News:New research finds no evidence that popular slimming supplements facilitate weight loss 2Health News:New research finds no evidence that popular slimming supplements facilitate weight loss 3Health News:Pain, dry mouth may play role in sleep quality of head and neck cancer patients 2Health News:Pain, dry mouth may play role in sleep quality of head and neck cancer patients 3Health News:Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic 2Health News:Golden Age Resources, Inc Terminates Alliance with JK Development of Palm Beach County LLC. 2Health News:The Kristen Renee Foundation Continues to Fight for Frederick, MD for Answers from the EPA and Fort Deterick 2Health News:The Kristen Renee Foundation Continues to Fight for Frederick, MD for Answers from the EPA and Fort Deterick 3Health News:The Kristen Renee Foundation Continues to Fight for Frederick, MD for Answers from the EPA and Fort Deterick 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: